PLYMOUTH, Minn.--(BUSINESS WIRE)--ev3 Inc. (NASDAQ:EVVV), a global medical device company focused on improving the lives of patients with vascular disease through the development of innovative endovascular therapies, today announced that it will host an analyst meeting at the 19th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium today at 5:00 p.m., Eastern time, at the Renaissance Hotel in Washington, D.C. The analyst meeting will include presentations by leading endovascular specialists as well as members of the ev3 management team. ev3 will discuss financial guidance for the fourth quarter 2007 and its updated revenue and earnings guidance for fiscal 2008 that will reflect the recent completion of its merger with FoxHollow Technologies, Inc., and also the impact of restructuring charges, sales force integration, expense synergies and other developments since the announcement of the merger in July 2007.
